-
公开(公告)号：US20160003829A1
公开(公告)日：2016-01-07
申请号：US14770840
申请日：2014-03-15
申请人： MORPHOTEK, INC.
IPC分类号： G01N33/574
CPC分类号： G01N33/57419 , G01N2333/4742 , G01N2333/71 , G01N2333/78
摘要： Provided herein are methods for determining the risk that a subject diagnosed with colorectal cancer will develop a recurrence of colorectal cancer and methods of predicting clinical outcome for a subject diagnosed with colorectal cancer by a) determining the level of expression for each marker of a panel of markers in a panel of tumor compartments in a tumor tissue sample from the subject, wherein the panel of markers comprises at least two of TEM1, HIF2α, CAIX, PDGFRβ, fibronectin, collagen I, collagen IV, and CD31 and wherein the panel of tumor compartments comprises at least three tumor compartments of pure stroma, tumor, stromal vessel, and tumor vessel; b) determining the TAPPS score for said subject; and c) comparing the TAPPS score of the subject to the TAPPS score of a population of subjects diagnosed with colorectal cancer. Also provided are related computer-implemented methods and systems, kits, and tumor microarrays.
摘要翻译： 本文提供了确定诊断为结肠直肠癌的受试者将发展为结肠直肠癌复发的风险的方法以及通过以下方法确定被诊断患有结肠直肠癌的受试者的临床结果的方法：a）确定面板的每个标记物的表达水平 标记物在来自受试者的肿瘤组织样品中的一组肿瘤区室中，其中所述标志物组包含TEM1，HIF2α，CAIX，PDGFR＆bgr，纤连蛋白，胶原I，胶原IV和CD31中的至少两种，并且其中 肿瘤室包含至少三个纯基质，肿瘤，基质血管和肿瘤血管的肿瘤区域; b）确定所述受试者的TAPPS得分; 和c）将受试者的TAPPS得分与诊断为结肠直肠癌的受试者群体的TAPPS评分进行比较。 还提供了相关的计算机实现的方法和系统，试剂盒和肿瘤微阵列。
-
公开(公告)号：US20180196052A1
公开(公告)日：2018-07-12
申请号：US15876732
申请日：2018-01-22
申请人： MORPHOTEK, INC.
IPC分类号： G01N33/574
CPC分类号： G01N33/57419 , G01N2333/4742 , G01N2333/71 , G01N2333/78
摘要： Provided herein are methods for determining the risk that a subject diagnosed with colorectal cancer will develop a recurrence of colorectal cancer and methods of predicting clinical outcome for a subject diagnosed with colorectal cancer by a) determining the level of expression for each marker of a panel of markers in a panel of tumor compartments in a tumor tissue sample from the subject, wherein the panel of markers comprises at least two of TEM1, HIF2α, CAIX, PDGFRβ, fibronectin, collagen I, collagen IV, and CD31 and wherein the panel of tumor compartments comprises at least three tumor compartments of pure stroma, tumor, stromal vessel, and tumor vessel; b) determining the TAPPS score for said subject; and c) comparing the TAPPS score of the subject to the TAPPS score of a population of subjects diagnosed with colorectal cancer. Also provided are related computer-implemented methods and systems, kits, and tumor microarrays.
-
搜索结果
2 条记录 (耗时 0.012 秒)
